 MONTREAL, Sept. 23, 2021 GLOBE NEWSWIRE -- Knight Therapeutics Inc. TSX: GUD Knight, a pan-American ex-USA specialty pharmaceutical company, today announced that it has entered into a definitive agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte NASDAQ:INCY, for the exclusive rights to distribute tafasitamab sold as Monjuvi in the United States and Minjuvi in Europe and pemigatinib Pemazyre in Latin America. Under the terms of the agreement, Incyte will be responsible for the development, manufacture and supply to Knight of tafasitamab and pemigatinib, and Knight will be responsible for seeking the necessary regulatory approvals and distributing both medicines in Latin America. 